# US 7,608,598 B2 · Use of lipid conjugates in the treatment of conjunctivitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,598 B2
- Document ID: US7608598B2
- Status: Granted
- Kind: B2
- Application number: 11/475,240
- Filed: 2006-06-27
- Published: 2007-07-05
- Granted: 2009-10-27
- Earliest claimed: 2000-01-10
- Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem
- Inventors: Saul Yedgar
- Web page: https://patentgrep.com/patent/US7608598B2

## CPC

- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/717: Celluloses
- A61K 31/721: Dextrans
- A61K 31/727: Heparin; Heparan
- A61K 31/728: Hyaluronic acid
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 27/00: Drugs for disorders of the senses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.

## Claims

### Claim 1

A method of treating conjunctivitis in a subject comprising the step of contacting said subject with a compound represented by the structure of the general formula 1):
wherein
R1 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms;
R2 is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; and
Y is either nothing or a spacer group ranging in length from 2 to 30 atoms;
X is a physiologically acceptable monomer, dimer, oligomer, or polymer, and wherein
X is a glycosaminoglycan; and
n is a number from 1 to 1000;
wherein if Y is nothing the phosphatidylethanolamine is directly linked to X via an amide bond and if Y is a spacer, said spacer is directly linked to X via an amide or an esteric bond and to said phosphatidylethanolamine via an amide bond and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said conjunctivitis is viral conjunctivitis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said conjunctivitis is bacterial conjunctivitis.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said conjunctivitis is due to an allergen.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said conjunctivitis is due to an irritant.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is carboxymethylcellulose.

### Claim 9 (depends on 1)

The method according to claim 1, wherein R1 and R2 are palmitic acid moieties.

### Claim 10 (depends on 1)

The method according to claim 1, wherein R1 and R2 are myristic acid moieties.

### Claim 11 (depends on 1)

The method according to claim 1, wherein X is hyaluronic acid.

### Claim 12 (depends on 1)

The method according to claim 1, wherein X is heparin.

### Claim 13 (depends on 1)

The method according to claim 1, wherein X is chondroitin sulfate.